[{"orgOrder":0,"company":"Bio-innova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"THAILAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bio-innova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bio-innova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-innova \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"||Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"||Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Morepen Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Morepen Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Morepen Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Morepen Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Indoco Remedies Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indoco Remedies Limited \/ Inapplicable"},{"orgOrder":0,"company":"Peking University Third Hospital","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Peking University Third Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Peking University Third Hospital \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Peking University Third Hospital \/ AstraZeneca"},{"orgOrder":0,"company":"University Medical Center Utrecht","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University Medical Center Utrecht","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University Medical Center Utrecht \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"University Medical Center Utrecht \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"||Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"||Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"||Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"University of Florida","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florida \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"University of Florida \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ IQVIA"},{"orgOrder":0,"company":"German Diabetes Center","sponsor":"Advice Pharma Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"German Diabetes Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"German Diabetes Center \/ Advice Pharma Group","highestDevelopmentStatusID":"10","companyTruncated":"German Diabetes Center \/ Advice Pharma Group"},{"orgOrder":0,"company":"University of Florida","sponsor":"National Institute of Neurological Disorders and Stroke | University of Cincinnati | Medical University of South Carolina | Johnson & Johnson Innovative Medicine | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Neurology","graph2":"Phase III","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florida \/ National Institute of Neurological Disorders and Stroke | University of Cincinnati | Medical University of South Carolina | Johnson & Johnson Innovative Medicine | AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"University of Florida \/ National Institute of Neurological Disorders and Stroke | University of Cincinnati | Medical University of South Carolina | Johnson & Johnson Innovative Medicine | AstraZeneca"},{"orgOrder":0,"company":"National Institute of Cardiovascular Diseases, Pakistan","sponsor":"PharmEvo","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Hematology","graph2":"Phase III","graph3":"National Institute of Cardiovascular Diseases, Pakistan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Cardiovascular Diseases, Pakistan \/ PharmEvo","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Cardiovascular Diseases, Pakistan \/ PharmEvo"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"University of Karachi","sponsor":"PharmEvo Private Limited","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Undisclosed","graph2":"Phase I","graph3":"University of Karachi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"University of Karachi \/ PharmEvo Private Limited","highestDevelopmentStatusID":"6","companyTruncated":"University of Karachi \/ PharmEvo Private Limited"}]
Find Clinical Drug Pipeline Developments & Deals for Ticagrelor
Details :
Ticagrelor tablets are indicated to reduce the risk of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome.
Details :
Ticagrelor tablets are indicated to reduce the risk of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome.
Details :
Ticapen (ticagrelor) mechanism of action involves inhibiting platelet activation and aggregation by reversibly binding to the P2Y12 receptor, to reduce the risk of stroke and heart attack.
Sponsor :
National Institute of Neurological Disorders and Stroke | University of Cincinnati | Medical University of South Carolina | Johnson & Johnson Innovative Medicine | AstraZeneca
Sponsor :
National Institute of Neurological Disorders and Stroke | University of Cincinnati | Medical University of South Carolina | Johnson & Johnson Innovative Medicine | AstraZeneca
Reset All
